Progression through the cell division cycle is driven by cyclins, which bind to and activate their catalytic partners, the cyclin-dependent kinases (CDKs). Specific heterodimeric cyclin-CDK complexes phosphorylate a plethora of cellular proteins to promote entry into and progression through the G1 phase of the cell cycle, to drive DNA synthesis (during S phase) and to trigger segre gation of the newly duplicated chromosomes to the daughter cells during mitosis, thereby ensuring that the cell cycle progresses in an ordered manner 1, 2 . Mammalian cyclin and CDK families each contain more than 20 members 3 , but only a few cyclin-CDK complexes are known to directly participate in the cell division cycle (FIG. 1) . Growth factors induce the expression of D-type cyclins (cyclins D1, D2 and D3), which are therefore regarded as molecular links between the cell environment and the core cell cycle machinery. Once induced, D-type cyclins interact with CDK4 or CDK6 and phosphorylate the pocket proteins pRB, p107 and p130, which bind to and regulate E2F transcription factors during the G1 phase of the cell cycle. Later during G1, E-type cyclins (cyclins E1 and E2) become upregulated and activate CDK2 (and, to a lesser extent, CDK1 and CDK3), resulting in phosphorylation of a broader range of cell cycle-related proteins. The subsequent induction in S phase of cyclin A2, which partners with CDK2 and CDK1, and the activation of cyclin B1-CDK1 at the onset of mitosis, drive the progression of cells through the remainder of the cell cycle through the phosphorylation of a large number of proteins that are involved in DNA replication, as well as in centrosome and chromosome function 1, 2, 4, 5 . Consistent with a role for cyclin-CDK complexes in promoting cell cycle progression, amplification, genetic rearrangements and/or overexpression of cyclin or CDK genes have been documented in nearly all human tumour types [6] [7] [8] [9] . In particular, the cyclin D1 gene (CCND1) is the second most frequently amplified locus across all human cancers. For these reasons, cyclin-CDK complexes are considered to be promising targets for cancer therapy.
. Consistent with a role for cyclin-CDK complexes in promoting cell cycle progression, amplification, genetic rearrangements and/or overexpression of cyclin or CDK genes have been documented in nearly all human tumour types [6] [7] [8] [9] . In particular, the cyclin D1 gene (CCND1) is the second most frequently amplified locus across all human cancers. For these reasons, cyclin-CDK complexes are considered to be promising targets for cancer therapy.
Although the canonical role of cyclins and CDKs as essential drivers of cell cycle entry and progression has been firmly established (FIG. 1) , research carried out over the past two decades provides increasing evidence for additional functions of these proteins in gene transcription, DNA damage repair, cell death, cell differentiation and metabolism. In this Review, we focus on the main biological areas in which such non-canonical functions of cyclins and CDKs have been documented. We restrict our Review to interphase cyclins and CDKs -that is, those operating in the G1, S and G2 phases. Non-cell cycle CDKs, such as CDK5, are only discussed in the context of their interactions with interphase cyclins, such as cyclin E-CDK5 function in post-mitotic neurons.
Kinase-dependent roles in transcription
In the current model of cell cycle regulation, the main function of cyclin D-CDK4 and cyclin D-CDK6 complexes is to phosphorylate and inactivate pocket proteins, thereby enabling the transcription of genes that are required for cell cycle progression 2, 5, 10 . In addition, cyclin D-CDK complexes have been shown to phosphorylate several transcription factors, thereby linking the cell cycle and transcription (TABLE 1) . Cyclin D-CDK4 complexes phosphorylate SMAD3, which inhibits the anti-proliferative effect of signalling through the transforming growth factor-β pathway 11 (FIG. 1) . Cyclin D-CDK4 and cyclin D-CDK6 complexes activate the transcription factor forkhead box protein M1 (FOXM1),
Chromatin modifier
A protein complex that, through catalysing specific histone or DNA modifications, induces changes in chromatin to make it accessible (open) or inaccessible (closed) to the transcriptional machinery.
which regulates the expression of various cell cycle regulators, including proteins that govern the G2-M transition 12 . Cyclin D1-CDK4-mediated phosphorylation of methylosome protein 50 increases the activity of the chromatin modifier PRMT5 (protein Arg N-methyltransferase 5), which is thought to mediate key events associated with cyclin D1-CDK-dependent neoplastic growth 13 . In addition, E-type and A-type cyclins have been implicated in directly modulating transcription through CDK-dependent phosphorylation of several DNA-binding factors, including SMAD3 and FOXM1 (REFS 11, 14) , inhibitor of DNA binding 2 (ID2), upstream-binding factor (UBF) and nuclear transcription factor Y (NFY) [15] [16] [17] [18] [19] [20] (FIG. 1) . Cyclin E/A-CDK2 complexes also phosphorylate the transcription factors MYC and B-MYB, thereby enhancing the ability of these proteins to activate target genes during the cell cycle 21, 22 . In tumours driven by MYC overexpression, CDK2 activity seems to be essential for preventing senescence and allowing immortalization of cancer cells 23 . However, whereas the functional link between cyclin-CDKs and pocket proteins has been firmly established, the contribution of these additional phosphorylation events to normal cell cycle progression remains unknown.
Kinase-independent transcriptional roles
In addition to the role of cyclin-CDK complexes in phosphorylating transcriptional regulators, there is substantial evidence for transcriptional functions of cyclins that do not involve kinase activity. Interestingly, reports of cell cycle-independent transcriptional roles of cyclins and CDKs have, so far, been vastly dominated by D-type cyclins.
D-type cyclins have direct roles in transcription.
The first indication of a pRB-independent role of cyclins in transcriptional control came from the demonstration that ectopic expression of cyclin D1 abrogated the ability of the myogenic master regulator myoblast determination protein (MYOD) to activate the muscle creatine kinase (MCK) promoter 24 . In skeletal myoblasts, Cell cycle progression is driven by heterodimeric complexes formed by cyclin D, cyclin E, cyclin A or cyclin B with cyclin-dependent kinase 4 (CDK4), CDK6, CDK2 or CDK1. Cyclin C-CDK3 complexes also participate in G0 to G1 phase progression (not shown), although their physiological relevance in this process is less well established. Cell cycle entry is driven by the formation of cyclin D-CDK4/6 complexes in response to mitogenic stimulation. These complexes phosphorylate and partially inactivate pRB, thereby releasing its inhibition of the E2F transcription factors. E2Fs subsequently promote the expression of multiple cell cycle genes, among which are those encoding E-type cyclins, which bind to and activate CDK2 (and, to a lesser extent, CDK1). Activation of CDK2 (and CDK1) by E-type and A-type cyclins leads to the phosphorylation of various transcription factors, including the helix-loop-helix (HLH) protein inhibitor of DNA binding 2 (ID2), as well as upstream binding factor (UBF), nuclear factor Y (NFY), B-MYB and MYC, which contribute to cell cycle progression at different levels. Cyclin D1-CDK4 complexes also phosphorylate chromatin modifiers such as the protein Arg N-methyltransferase 5 (PRMT5) cofactor methylosome protein 50 (MEP50) to promote the repression of specific genes with anti-proliferative properties. Several cyclin-CDK complexes can phosphorylate the transcription factor SMAD3, which is activated by anti-mitogens such as transforming growth factor-β (TGFβ) and forkhead box protein M1 (FOXM1), to promote cell cycle progression. Entry into mitosis is specifically driven by cyclin B-CDK1 complexes. Dashed arrows indicate indirect connections or connections with multiple steps. cyclin D1 recruits CDK4 to MYOD and thereby blocks MYOD-dependent transcription independently of CDK4 catalytic activity [25] [26] [27] . Cyclin D1 was also shown to repress transcription factor SP1-mediated transcription by binding to the TATA box-binding protein (TBP)-associated factor TAFII250 in a pRB-independent manner 28, 29 . A direct interaction between cyclin D1 and the oestrogen receptor has been reported to augment oestrogen receptor-driven transcription, independently of the kinase activity of CDKs. Specifically, cyclin D1 was shown to function as a scaffold between the oestrogen receptor and members of the steroid receptor coactivator family 30, 31 , as well as between the oestrogen receptor and the chromatin modifier histone acetyltransferase PCAF (also known as KAT2B) 32 . By contrast, cyclin D1 and cyclin D3 inhibit the transactivation activity of the androgen receptor, which is another member of the nuclear steroid hormone receptor family, in a kinase-independent manner by competing with it for PCAF binding [33] [34] [35] [36] . Numerous reports have subsequently described interactions of D-type cyclins with many transcription factors (TABLE 1) . Several groups have demonstrated, mostly using protein-overexpression systems, that D-type cyclins interact with sequence-specific transcription factors and activate or repress transcription by recruiting chromatin modifiers to gene promoters (or, in some cases, by blocking their access). Cyclin D1 directly binds to and inhibits histone acetyltransferases such as p300 and CREB-binding protein (CBP) -in addition to PCAF -and represses their ability to activate vari ous promoters, including that of peroxisome proliferatoractivated receptor-γ (PPARγ), a master regulator of adipo genesis 32, 37 . Consistent with these data, mouse embryonic fibroblasts lacking cyclin D1 have increased PPARγ activity and are prone to adipogenic differentiation 38 . Cyclin D1 can also repress transcription through neurogenic differentiation factor 1 (NEUROD1) or runt-related transcription factor 3 (RUNX3), independently of CDK activity, by preventing the inter action of these transcription factors with p300 (REFS 39, 40) . Furthermore, cyclin D1 can inhibit the transcriptional activity of thyroid hormone receptors by recruiting histone deacetylases to these transcription factors and by promoting the formation of transcriptional repressive complexes 41 . Cyclin D2 and cyclin D3 can also modulate the activity of several transcription factors by interacting directly with them. A yeast two-hybrid screen identified the MYB-like transcription factor DMP1 (dentin matrix acidic phospho protein 1) as a cyclin D2 interactor 42 . Enforced expression of any D-type cyclin inhibits the transcriptional activity of DMP1 in a CDK-independent manner 42, 43 . Intriguingly, DMP1 regulates the expression of p19 ARF -which is an inhibitor of E3 ubiquitin-protein ligase MDM2, a negative regulator of p53 -raising the possibility that D-type cyclins can modulate both the pRB pathway (through CDK activity) and the p53 pathway (through CDK-independent activity).
Cyclin D3 was reported to interact with and enhance the transactivation of the vitamin D receptor, and this effect was diminished by overexpression of CDK4 or CDK6 (REF. 44 ). Additionally, cyclin D3 interacts with human activating transcription factor 5 (ATF5) and enhances its activity 45 . However, cyclin D3 also competes with core binding factor-β for binding to RUNX1 (also known as AML1), thereby reducing the ability of RUNX1 to bind to DNA and activate transcription 46 . Collectively, these reports suggest that D-type cyclins might exert transcriptional effects independently of any associated kinase activity. To further address this, human cancer cells were engineered to overexpress wildtype cyclin D1 or a mutant cyclin D1 that is unable to activate CDK4 and CDK6 (REF. 47) . Surprisingly, the set of induced target genes was identical in both cases and lacked E2F target genes, indicating that cyclin D1 has a kinase-independent and E2F-independent role in transcription. Further computational analysis implicated the transcription factor CCAAT/enhancer-binding protein β (CEBPβ) as the effector of cyclin D1 in regulating gene expression. Proteomic studies using a knock-in mouse strain expressing a tagged version of cyclin D1 in place of the wild-type protein showed that cyclin D1 interacts in vivo with several proteins that are involved in transcription 48 . Furthermore, chromatin immunoprecipitation coupled to microarray (ChIP-on-chip) analysis revealed an extensive interaction of cyclin D1 with the mouse genome 48 . In particular, within developing mouse retinas, cyclin D1 physically occupies the Notch1 gene enhancer, to which it recruits CBP acetyltransferase, thereby activating gene expression. Genetic ablation of cyclin D1 decreased recruitment of CBP to the Notch1 gene enhancer and diminished histone acetylation and expression of NOTCH1 in the retina. Given the essential role of NOTCH1 in retinal development 49 , these findings are likely to explain, at least in part, the retinal developmental abnormalities that are seen in cyclin D1-null animals 50, 51 . A direct interaction of cyclin D1 with chromatin was also demonstrated by a ChIP-sequencing study in which tagged cyclin D1 was ectopically expressed in cyclin D1-null mouse embryonic fibroblasts. The authors concluded that cyclin D1 has a role in chromosomal stability through binding to genes that govern chromosomal integrity 52 .
Direct transcriptional f unctions of CDK6.
Although the majority of reports have highlighted a CDK4/6-independent function of D-type cyclins in regu lating transcription, some intriguing studies revealed a kinase-independent role for CDK6 itself in this process. CDK6 was shown to physically interact with and inhibit the transcriptional activity of RUNX1 in a kinase-independent fashion and, by doing so, block myeloid differentiation 53 . CDK6, but not CDK4, activates JUN and signal transducer and activator of transcription 3 (STAT3) to induce transcription of cyclin-dependent kinase inhibitor 2a (Cdkn2a; encoding the CDK4/6 inhibitor p16
INK4A
) and vascular endothelial growth factor A (Vegfa). Whereas the effect of CDK6 on p16
INK4A expression requires the presence of a D-type cyclin, the effect on VEGFA expression is independent of cyclin D 54 . Interestingly, cyclin D1 has also been postu lated to contribute to VEGFA gene transcription 55 , A post-mitotic state in which cells do not divide, although they may be induced to re-enter the cell cycle in response to specific stimuli.
D-loops
Displacement loops formed in homologous recombination repair. Two strands of a homologous chromosome are separated for a stretch by an invading broken strand, forming a displaced single-stranded structure, the D-loop.
suggesting that both CDK6 and cyclin D1 may regulate angiogenesis through different routes. The observation that CDK6 upregulates its own inhibitor p16 INK4A indicates the presence of a negative feedback loop, by which CDK6 safeguards against uncontrolled proliferation triggered by CDK6 overexpression 54 . CDK6 can exert its pro-proliferative role only upon silencing of the gene encoding p16 INK4A , an event that is frequently seen in human tumours 6 . Additional data suggest that the transcriptional activity of CDK6 may also be crucial in regulating the balance between quiescence and proliferation in haematopoietic and leukaemic stem cells by modulating the activity of the transcription factor early growth response protein 1 (EGR1) 56 , although whether CDK6 binds directly to EGR1 is currently unknown.
Cyclins and CDKs in DNA damage repair DNA double-strand breaks (DSBs) are repaired by two distinct mechanisms: the high-fidelity homologous recombination, which uses the sister chromatid as the main template for repair; and non-homologous end-joining (NHEJ), which directly joins the broken DNA and is therefore error-prone. Work in several systems indicates that components of the core cell cycle machinery have important and direct roles in DSB repair.
Yeast. In Saccharomyces cerevisiae, inhibition of the sole cyclin-dependent kinase Cdc28 (which is homologous to CDK1) after the induction of DSBs causes defects in end-resection of damaged DNA, thereby preventing the loading of the homologous recombination repair proteins Rad51 and replication protein A to sites of DNA damage 57, 58 ; when Cdc28 is inhibited before the induction of DSBs, the incidence of error-prone NHEJ increases substantially, indicating that the kinase activity of Cdc28 is necessary to support homologous recombi nation 57 (FIG. 2a) . In Schizosaccharomyces pombe, the CDK1 homologue Cdc2 promotes the formation of Rad51 foci, resulting in the formation of recombination intermediates at early stages of homologous recombination. At a later stage of repair, Cdc2 and a checkpoint protein Crb2 were shown to control topoisomerase III activity, thereby ensuring complete processing of recombi nation intermediates 59 . S. cerevisiae Cdc28 can also regulate DNA damage repair by phosphorylating various substrates, such as Sae2, an endonuclease that is required for the initi ation of resection of single-stranded DNA 60 . Another substrate of the S. cerevisiae Cdc28 is the Srs2 helicase, the phosphorylation of which prevents its sumoylation and targets it to dismantle specific DNA structures, such as D-loops, in a helicase-dependent manner during homologous recombination 61 . During DNA damage repair, Cdc28 also phosphorylates the G2 checkpoint protein Rad9 and the resection nuclease Dna2 (REF. 65 ). Collectively, these studies present a strong case for the requirement of CDK activity in the resection of DSB ends and in mediating the choice between the homologous recombination and NHEJ repair pathways in yeast 66 .
Mammals.
In contrast to yeast, cyclin A-and cyclin B-associated CDK activity was found to inhibit homolo gous recombination in mammalian cells. Cyclin A-CDK1/2 and cyclin B-CDK1 complexes phosphorylate Ser3291 of breast cancer type 2 susceptibility protein (BRCA2) 67 , thereby preventing it from binding to and recruiting RAD51 to sites of DNA damage (FIG. 2b) . DNA damage leads to reduced levels of Ser3291 phosphorylation and restoration of the interaction between BRCA2 and RAD51 (REF. 67 ). Phosphorylation of Ser3291 is low in S phase but increases towards mitosis, suggesting that the termination of homologous recombination by CDKs is necessary for normal chromosome segregation. Consistent with this, expression of mutant forms of BRCA2 that cannot be phosphorylated by CDK does not change the rate of homologous recombin ation but delays the onset of mitosis 68 . CDK2 was also shown to support homologous recombination by phosphorylating C-terminal binding protein (CTBP)-interacting protein (CTIP; the human homologue of Sae2), thereby promoting its interaction with BRCA1 and the MRE11 exonuclease and leading to the resection of DSBs 69 (FIG. 2b) .
As a consequence of DNA damage, cyclin D1 is degraded and cyclin D-CDK4/6 complexes are disrupted, which contributes to cell cycle arrest 70 . Expression of degradation-resistant mutants of cyclin D1 results in increased levels of DNA damage, confirming the importance of preventing cell cycle progression in these conditions 71 . An unexpected direct role for cyclin D1 in DNA damage repair was first suggested by the observation that targeting cyclin D1 to chromatin led to co-recruitment of RAD51 (REF. 72 ). Subsequently, it was reported 73 that cyclin D1 localizes -in a BRCA2-dependent mannerto irradiation-induced DSBs in human cancer cells, where it helps to recruit RAD51, thereby stimulating homologous recombination (FIG. 2b) . Depletion of cyclin D1 in human cancer cells reduced the recruitment of RAD51, decreased homologous recombination and rendered cells more sensitive to DNA damage. Notably, this function of cyclin D1 was shown to be kinase-independent and to also take place in pRB-deficient cells 73 . A positive role for cyclin D1 in DNA damage repair might seem to be inconsistent with the observation that cyclin D1 is rapidly degraded after DNA damage. However, a relatively small pool of cyclin D1 persists after irradiation, and cyclin D1 becomes redistributed to DNA damage sites. This DNA-bound pool of cyclin D1 is likely to have a positive role in DNA damage repair 73 .
On the other hand, forced overexpression of cyclin D1 might override cell cycle arrest following DNA damage, leading to DNA replication stress and, ultimately, apoptosis. Consistent with this notion, overexpression of cyclin D1 in cultured tumour cells rendered the cells more sensitive to radiation and triggered apoptosis 74, 75 . One important and unresolved issue is how overexpression of cyclin D1, which is frequently observed in human cancers, affects the response of tumour cells to DNA damage in vivo.
Balancing cell proliferation and death
The regulation of the cell cycle is tightly linked to the control of cell death. Indeed, early studies indicated that the pRB-E2F pathway could modulate the expression of multiple pro-or anti-apoptotic proteins 5, 76 . Overexpression of cyclins in cultured cells leads to either increased apoptosis or increased survival, depending on the cellular setting. For instance, ectopic expression of cyclin D1 induces cell death and increases sensitivity to cytotoxic agents in various cell lines 74, [77] [78] [79] [80] [81] . By contrast, overexpression of cyclin D1 protects fibrosarcoma cells from cell death 82 , and suppression of cyclin D1 using antisense oligonucleotides sensitizes pancreatic cancer cells to apoptosis induced by cytotoxic agents 83 . Similarly, ectopic expression of cyclin D3 in leukaemic T cells prevents them from apoptosis that would normally be induced by phorbol myristate acetate 84 , and ablation of cyclin D3 in T cell acute leukaemia cells triggers cell death 85 . Whether these effects are direct or mediated by the pRB-E2F pathway is unclear in most of the cases. However, D-type cyclins and CDKs can also modulate apoptotic cell death through direct interaction with the apoptotic machinery. In mantle cell lymphoma, cyclin D1, which is frequently over expressed in this tumour type, binds to and sequesters the pro-apoptotic protein BAX in the cytoplasm, thereby inhibiting apoptosis 86 (FIG. 3) . CDK4 interacts with the apoptosis inhibitor survivin (also known as baculoviral IAP repeatcontaining protein 5). As a result, p21 CIP1 is released from its complex with CDK4 and interacts with mitochondrial pro-caspase 3 to suppress FAS-mediated cell death 87 . A pro-apoptotic function for cyclin D3 is suggested by the observation that it can physically interact with caspase 2, leading to the stabilization of this protease and promoting its cleavage into an active form 88 (FIG. 3) .
Cyclin D1-CDK kinase activity might play a part in mediating cell death under pathological conditions. Increased activity of cyclin D1-CDK4, correlating with neuronal death, has been reported in a rat model of stroke 89 . Moreover, neuronal cell death triggered by treatment of rats with kainic acid can be prevented by injection of CDK4 or cyclin D1 antisense oligonucleotides into brain ventricles 90 . Administration of flavopiridol, which is a pharmacological inhibitor of CDKs, into brain ventricles prevents neuronal cell death in a model of focal ischaemia Interphase cyclins modulate apoptosis using cyclin-dependent kinase (CDK)-dependent and CDK-independent mechanisms. Cyclin E-CDK2 complexes phosphorylate the pro-survival factor induced myeloid leukaemia cell differentiation protein MCL1, as well as the transcription factor forkhead box protein O1 (FOXO1), leading to the inhibition or activation of apoptosis, respectively. Phosphorylation of MCL1 stabilizes the protein, whereas phosphorylation of FOXO1 leads to upregulated expression of the pro-apoptotic factors FAS and BIM. Binding of survivin to CDK4 causes the release of the CDK inhibitor p21 (CIP1), which binds to and inhibits caspase 3. D-type cyclins can also directly interact with the pro-apoptotic proteins BAX or caspase 2. Moreover, the three D-type cyclins have overlapping roles in repressing the expression of the death receptor FAS and its ligand FASL, thereby preventing apoptosis in haematopoietic cells. Cyclin D1 also interacts with FOXO1 and FOXO3A and prevents anoikis. Dashed arrows indicate indirect connections or connections with multiple steps.
Autophagy
The degradation and recycling of cellular components and organelles by lysosomes.
Anoikis
A special form of programmed cell death that can be induced in anchorage-dependent cells by their detachment from the surrounding matrix.
Basic helix-loop-helix (bHLH) transcription factor
A protein that contains two helices separated by a loop (the HLH domain), which binds to DNA in a sequence-specific manner. (FIG. 3) ; ablation of the three D-type cyclins results in upregulation of FAS and FASL proteins, leading to haematopoietic cell apoptosis 92 . Evidence for a direct role of cyclin E-CDK2 or cyclin A-CDK2 complexes in the control of cell death is more limited. Cyclin E-CDK2 affects the apoptotic response through phosphorylation of the transcription factor FOXO1, thus upregulating the expression of the pro-apoptotic proteins FAS and BIM (also known as BCL2L11) 93 . However, it has also been suggested that cyclin E-CDK2 complexes promote survival by directly phosphorylating the anti-apoptotic factor induced myeloid leukaemia cell differentiation protein MCL1 (REF. 94) (FIG. 3) .
triggers massive apoptosis. In this compartment, D-type cyclins repress the expression of death receptor FAS and its ligand FASL
Cyclins and CDKs can modulate other cell death pathways in addition to apoptosis. Cyclin D1 expression suppresses autophagy in the mammary epithelium 95 , a function that may be mediated by the pRB-E2F pathway 96 . In prostate cancer cell lines, cyclin D1 was postu lated to inhibit anoikis by binding to FOXO1 and FOXO3A and blocking their ability to induce anoikis in a CDK-independent manner 97 (FIG. 3) .
Control of cell differentiation
Terminal differentiation is usually coupled to permanent exit from the cell cycle. The levels of cyclins typically decline when cells exit the cell cycle and undergo differ entiation. Moreover, induction of the expression of CDK inhibitors during cell differentiation prevents activation of cyclin-CDK complexes in terminally differentiated cells
. On the other hand, expression of cyclin-CDK complexes in proliferating cells inhibits pRB function, thereby promoting proliferation and inhibiting differentiation. Indeed, pRB -in addition to its well-established role in the cell cycle -binds to and regulates the activity of several cell type-specific transcription factors, including MYOD, myocyte-specific enhancer factor 2 (MEF2), RUNX2 and many others, thereby linking cell cycle arrest and differentiation 5 . Cyclins and CDKs have also been shown to carry out direct, pRB-independent functions in cell differentiation. For example, cyclin D1-CDK4 complexes phosphorylate RUNX2, a transcription factor that drives osteoblast differentiation, and target it for degradation, thereby inhibiting bone differentiation 98 . It is likely that CDK1 and CDK2 can affect cell differentiation through phosphorylation and activation of EZH2, the catalytic subunit of the histone Lys methyltransferase Polycomb repressive complex 2 (PRC2). PRC2 is an important regulator of gene expression through catalysing the trimethylation of histone H3 Lys 27 (H3K27me3), and it influences differentiation by repressing lineage-specific genes 99, 100 .
Roles of cyclins and CDKs in muscle differentiation.
As mentioned above, cyclin D1 and CDK4 can prevent transcriptional activation mediated by MYOD and hence inhibit myoblast differentiation [24] [25] [26] [27] 101 (FIG. 4a) . Although this activity is partially kinase-independent, maximal repression of MYOD, as well as repression of another muscle-specific basic helix-loop-helix (bHLH) transcription factor, myogenin, requires CDK kinase activity 102 . Cyclin D-CDK4 complexes also block the association of MEF2 with glutamate receptor-interacting protein 1 (GRIP1), which is a member of the steroid receptor family of transcription co-activators, thereby inhibiting the ability of MEF2 to induce muscle gene expression 102 . This block requires CDK activity, although the exact molecu lar mechanism by which it is mediated is unclear 102 . Cyclin D1 can also inhibit the differentiation of cardio myocytes through CDK4-dependent phosphoryl ation of GATA4, which targets this transcription factor for degradation 103 (FIG. 4a) .
By contrast, specific D-type cyclins are upregulated during terminal differentiation of certain cell types. In differentiating skeletal myoblasts, the expression of cyclin D3 is strongly upregulated (over 20-fold), in part by MYOD 101, 104, 105 . In differentiated myotubes, cyclin D3 becomes stabilized by binding to pRB 106 (FIG. 4a) . High levels of cyclin D3 have also been observed in several other terminally differentiated cell types, including many types of epithelia, oocytes and ovarian corpora lutea, podocytes within renal glomeruli, adipocytes (see below) and cells of the exocrine pancreas [107] [108] [109] [110] . On the basis of these observations, cyclin D3 has been postulated to carry out cell cycle-independent functions in a range of terminally differentiated cells. However, these findings seem to be in conflict with the observation that mice lacking cyclin D3 develop normal muscle and epithelia 111 . This might be attributed to functional redundancy between the three D-type cyclins, and conditional knockout approaches involving deletion of all D-type cyclins in post-mitotic tissues may help to clarify this point.
Box 1 | Cyclin-dependent kinase inhibitors
Two different families of proteins can inhibit cyclin-dependent kinase (CDK) activity 159 . Members of the CIP/KIP (CDK-interacting protein/kinase inhibitory protein) family of inhibitors -p21 (CIP1), p27 (KIP1) and p57 (KIP2), encoded by the cyclin-dependent kinase inhibitor 1 (CDKN1) genes -bind to most cyclin-CDK complexes and prevent their activation. The CDKN2-encoded p16 (INK4A), p15 (INK4B), p18 (INK4C) and p19 (INK4D) proteins, which constitute the INK4 family, bind to CDK4 and CDK6 and block their association with the D-type cyclins. Owing to their inhibition of CDKs and cell proliferation, CDK inhibitors are tumour suppressors, and deletion of the CDKN2A-CDKN2B locus, which encodes p16, p15 and another protein p14 (ARF), which is involved in the activation of the p53 tumour suppressor, is one of the most frequent mutations in human tumours 160 . CDK inhibitors are involved in many cellular processes, including cell cycle control, transcription, cell migration and metabolism, and they can affect cell quiescence, senescence, differentiation or cell death, depending on the cellular setting 112, 143, 155, [161] [162] [163] [164] . In most cases, these functions are mediated by inhibition of specific cyclin-CDK complexes. However, INK4 or CIP/KIP proteins can have additional activities that are unrelated to their function as CDK inhibitors 165 . For example, p19 INK4D has been proposed to participate in DNA damage repair and senescence in a CDK-independent manner through directly interacting with chromatin 166, 167 . p21
CIP1 can function as a RHO-kinase (ROCK) inhibitor, and p57 KIP2 modulates the subcellular localization of LIM kinase (LIMK), a Ser/Thr kinase involved in the regulation of actin filaments 168 .
Similarly, p27
KIP1 has an important role in the control of cytoskeleton assembly and migration 169 by physically interacting with RHOA and by blocking its activation, resulting in impaired stabilization of actin fibres and increased cell motility 170, 171 .
Asymmetric cell divisions
Special form of cell division in which the daughter cells have different fates, probably as a consequence of asymmetric distribution of cellular components during division.
Cyclin D-CDKs in neuronal development. Cyclin-CDK complexes can inhibit neuronal differentiation, not only through the pRB-E2F pathway 112 but also by phosphoryl ating and inactivating transcription factors that drive neurogenesis. For instance, neurogenin 2 (NGN2), which is a master regulator of neuronal differentiation, is inhibited by multi-site phosphorylation by CDKs 113, 114 (FIG. 4b) , and a non-phosphorylatable NGN2 mutant can drive neuronal differentiation in the presence of CDK activity 113 . Cyclin D1-CDK4 activity in neural stem cells is also thought to inhibit neuro genesis and expand the population of basal progenitors by shortening the duration of G1, although the exact mechanism remains to be clarified 115 . In support of a role for cyclin-CDK complexes in inhibiting neuronal differentiation, embryos from Cdk2
Cdk4
−/− knockout mice lack the intermediate zone and cortical plate in their brains, owing to premature neuronal differentiation and depletion of basal progenitor cells 116 .
Other data support the opposite conclusionnamely, that D-type cyclins promote neuro genesis. A cell cycle-independent function for cyclins in the nervous system was first proposed based on the upregulation of cyclin D1-associated kinase activity in rat brains at the onset of neuronal differentiation 117, 118 . High levels of cyclin D1 persisted in the brains of adult mice, whereas the levels of cyclin D2 decreased, suggesting a specific role for cyclin D1 in neuronal differenti ation. By contrast, another study observed high levels of cyclin D2 in the brains of adult mice, suggesting that cyclin D2 has a distinct role in terminally differentiated neurons 119 .
Loss-of-function and gain-of-function experiments in embryonic chick spinal cord also supported a role for cyclin D1 in promoting neuronal differentiation 120 . In vivo knockdown of cyclin D1, but not cyclin D2, signifi cantly reduced differentiation of motor neuron progenitors. Conversely, forced overexpression of cyclin D1 enhanced neurogenesis, whereas cyclins D2 and D3 inhibited this process. Interestingly, overexpression of a cyclin D1 mutant that is unable to activate CDKs promoted neurogenesis to an even greater extent than wild-type cyclin D1 (REF. 120 ). Collectively, these findings suggest a differential role for cyclins D1 and D2 in neurogenesis, but the molecular mechanisms involved remain unclear.
Roles of cyclin E in neuronal development. Cell cycle proteins also affect the balance between progenitors and neurons by controlling the regulation of asymmetric cell divisions of neural progenitors 121 . In Drosophila melano gaster, cyclin E is expressed in the thoracic cell lineage, which undergoes asymmetric divisions that give rise to neuroblasts (central nervous system stem cells in D. melanogaster) and to glial progenitors. Depletion of cyclin E renders the thoracic lineage capable of generating only glial progenitors, whereas ectopic expression of cyclin E in the abdominal lineage forces it into asymmetric divisions 122 . Mechanistically, cyclin E interacts with and inhibits the activity of Prospero, which is a transcription factor required for glial cell identity 123 . The role of E-type cyclins in asymmet ric cell divisions of mammalian neural progenitors has not been explored. b Nervous system a Muscle Figure 4 | Roles of interphase cyclins and cyclin-dependent kinases in cell differentiation. a | In muscle progenitor cells, cyclin D1 interacts with the transcription factor myoblast determination protein (MYOD) and inhibits its activity. This effect requires cyclin-dependent kinase 4 (CDK4) but is partially independent of its kinase function. However, the catalytic activity of CDK4 is required for the inhibition by cyclin D1-CDK4 of GRIP1-MEF2 (glutamate receptorinteracting protein 1-myocyte-specific enhancer factor 2) complexes, which are also involved in muscle differentiation. Cyclin D1-CDK4 complexes also phosphorylate and inactivate the GATA4 transcription factor, and thereby repress the differentiation of cardiomyocytes. Conversely, cyclin D3, which is stabilized in differentiated muscle cells by its interaction with pRB, seems to promote muscle cell differentiation by an unknown mechanism. b | In the nervous system, the differentiation of neuronal progenitors into neurons is blocked by cyclin A-CDK2 complexes, which phosphorylate and inactivate the neurogenin 2 (NGN2) transcription factor. Cyclin E regulates synaptic plasticity by forming kinase-inactive complexes with CDK5 and sequestering it from its activators p35 and p39, thereby inhibiting the phosphorylation of synaptic CDK5 substrates. Dashed arrows indicate indirect connections or connections with multiple steps.
Transplants from genetically non-identical individuals of the same species.
Exocyst complex
A highly conserved, octameric protein complex that regulates vesicle delivery to, and docking at, the cell surface.
Interestingly, cyclin E is upregulated in the brains of postnatal animals as neurons undergo terminal differentiation. In terminally differentiated neurons, cyclin E forms a complex with CDK5 (REF. 124) (FIG. 4b) , which is a well-established regulator of neuronal differentiation 125 . Cyclin E sequesters CDK5 into kinase-inactive cyclin E-CDK5 complexes, away from the CDK5-activating partners p35 and p39. Through this mechanism, cyclin E controls phosphorylation of key synaptic proteins and regulates synaptic plasticity and memory formation. Ablation of cyclin E in mouse brains decreased synaptic function and rendered animals unable to normally retain memories 124 . These findings raise the possibility that abnormalities in cyclin E levels may underlie some cases of human learning disabilities 124 .
Immune system differentiation and function. A role for CDK2 in suppressing immune tolerance was highlighted by observations that when cardiac allografts were transplanted into CDK2-null recipient mice, a long-term allograft acceptance was observed, in contrast to wild-type recipients, which rejected the grafts 126 . CDK2-deficient regulatory T cells (Tregs) displayed increased suppressive capacity, probably explaining the increased immune tolerance in CDK2-null mice 126, 127 . Cyclin E-CDK2 was shown to phosphorylate and negatively regulate FOXP3, a transcription factor that is required for the development and function of Tregs 128 . Furthermore, in developing lymphocytes, cyclin A-CDK2 triggers the periodic degradation of the recombinase RAG2 (V(D)J recombination-activating protein 2), thereby restricting V(D)J recombination to G1 phase 129 .
Mutation of CDK2-substrate residues of RAG2 abrogated cell cycle-dependent degradation of this protein 130 .
Regulation of cell migration
During keratinocyte differentiation, cyclin D1 colocalizes with SEC6 (also known as EXOC3; a subunit of the exocyst complex involved in vesicle trafficking), as well as with β1 integrin and RALA (a GTPase that regulates the exocyst). Ectopic overexpression of cyclin D1 increases recycling of β1 integrin upon differ entiation, as demonstrated by a pronounced loss of membrane-bound β1 integrin, and leads to reduced keratinocyte adhesion to the extracellular matrix 131 . Cell migration and the actin cytoskeleton are also modulated by cyclins and CDKs at different levels 132 . CDK6 was shown to localize to the ruffling edges of spreading fibroblasts prior to the formation of filamentous actin and to promote migration in a α v β 3 integrin-dependent manner 133 . Cyclin D1 was implicated in promoting fibroblast migration by inhibiting the thrombospondin 1 and RHO kinase (ROCK) signalling pathways 134 . Cyclin D1 can also enhance cell migration by negatively regulating the transcription of the E3 ubiquitin ligase factor SKP2 (S-phase kinaseassociated protein 2) 135 . SKP2 promotes the degradation of the CDK inhibitor p27 KIP1 , which has been implicated in cell migration through control of the RHOA pathway 136 
. Cyclin D1 can also affect cell migration by binding to and promoting the phosphoryl ation of filamin A, a member of the actin-binding filamin protein family. Knockdown of cyclin D1 or ectopic expression of p16
INK4A reduced the phosphorylation of filamin A and of many other actin-binding proteins, suggesting a direct role for a cyclin D1-associated kinase in regulating the cytoskeleton 137 . Furthermore, it was postulated that cyclin D1 effects cell migration in a CDK-independent manner by transcriptionally regulating DICER 138 , which is an endoribonuclease required for microRNA processing. In summary, although cyclin D1 has been shown to promote cell migration in several cell types, the main mechanism responsible for this function remains unclear. It also remains to be seen whether over expression of cyclin D1, as observed in many cancer types, contributes to the increased invasiveness of tumour cells.
Roles of cyclins and CDKs in metabolism
Multiple cellular functions of cyclins and CDKs converge to control the generation of cellular energy and metabolism at both the cellular and organismal levels.
Cellular energy production and metabolism. In D. mela nogaster and in mammalian cells, cyclin D-CDK4 activity positively regulates mitochondrial biogenesis, through pRB-E2F-dependent control of mito chondrial transcription factors such as nuclear respiratory factor 1 (NRF1) and NRF2 (REF. 139) (FIG. 5) . By contrast, cyclin D1-CDK4 can also inhibit mitochondrial function: depletion of cyclin D1 in mouse breast cancer cells in vivo promoted expression of genes involved in mitochondrial function and increased the number of mitochondria 140 , and cyclin D1-null mouse mammary epithelial cells had increased mitochondrial size 140 . The inhibitory effects of cyclin D1 on mitochondrial function were attributed to mediating the repression of NRF1 through CDK-dependent phosphorylation, leading to impaired expression of mitochondrial transcription factor A (mtTFA), a factor that is essential for mitochondrial respiration 141 (FIG. 5) . Cyclin D1 was also shown to affect mitochondrial function by inhibiting the expression and activity of the glycolytic enzyme hexokinase 2 (REF. 140 ).
Cyclin D1 can also exert its effect on mitochondria independently of CDK4 by binding to the voltagedependent anion channel protein (VDAC) in the outer mitochondrial membrane, thereby preventing VDAC from binding to hexokinase 2 and impairing the access of ADP to the inner mitochondrial membrane 142 . Further observations that cyclin D1 can directly bind to additional lipogenic enzymes and mitochondrial proteins 48 point to cyclin D1 as an important regulator of metabolic activities through different pathways 143 . In addition to cyclin D1, cyclin E has been proposed to inhibit mitochondrial biogenesis and oxidative metabolism in a transcriptional manner, but the exact mechanism is unknown 144 . Finally, the cyclin B1-CDK1 complex was shown to localize to the matrix of mitochondria, where it phosphorylates various mitochondrial proteins, including the respiratory chain complex 1 subunits, leading to increased mitochondrial respiration. It was postulated that this event coordinates mitochondrial respiration with G2-M phase progression 145 .
Regulation of metabolism at the organismal level.
A physiological role for cell cycle proteins in metabolism was first documented by the observations that mice lacking CDK4 developed diabetes owing to the loss of pancreatic islet β-cells 146, 147 . Conversely, knock-in mice expressing a constitutively active CDK4 mutant developed pancreatic hyperplasia 146 . Mice lacking cyclin D2 also had substantially reduced β-cell mass and reduced islet size, leading to glucose intolerance 148 . This phenotype was further exacerbated by the additional heterozygous deletion of cyclin D1, and cyclin D1
−/− mice developed life-threatening diabetes by 3 months of age 149 . Ablation of cyclin D3 exacerbated diabetes in non-obese diabetic mice but did not affect the prolifer ation rate of β-cells, raising the possibility that cyclin D3 might have a cell cycle-independent role in this tissue 110 . Glucose challenge was proposed to promote cyclin D2-CDK4 complex formation and kinase activity, which indirectly induces the expression of KIR6.2, a component of the potassium ATP channel that positively regu lates insulin secretion 150 (FIG. 5) .
Conversely, inhibition of CDK4 activity leads to lower expression of KIR6.2, decreases insulin secretion and results in glucose intolerance 150 . The effect of cyclin D2-CDK4 activity on KIR6.2 levels is mediated by E2F1, but it occurs independently of cell cycle progression 150 . An independent mechanism linking insulin signalling to cyclin D1-CDK4 was provided by the observation that insulin-mediated upregu lation of cyclin D1 (and the subsequent activation of cyclin D1-CDK4) in hepatocytes leads to phosphoryl ation and activation of the histone acetyltransferase GCN5 (also known as KAT2A). GCN5 is responsible for acetylation and inhibition of the transcription factor PPARγ co-activator 1α (PGC1α) 151 , which inhibits the expression of gluconeogenesis genes, thereby suppressing hepatic glucose production 151 (FIG. 5) . Cyclin D1 was shown to inhibit lipid metabolism in the liver in a kinase-independent manner, through its interaction with and suppression of the transcription factor hepatocyte nuclear factor 4α 152 . The functions of cyclins and CDKs in modulating metabolic pathways contribute to the ability of these proteins to affect differentiation. A positive role for cyclin D3 in promoting adipocyte differentiation is supported by the observation that knockdown of cyclin D3 inhibits adipogenesis in vitro 153 . Consistent with these data, mice lacking cyclin D3 or CDK4 are protected from diet-induced obesity, and have smaller adipocytes and reduced expression of adipogenesis genes 109, 154 . CDK4 -probably in complex with cyclin D3 -also participates in adipocyte differentiation by directly inter acting with and activating PPARγ, the master regulator of adipo genesis 109, 154 (FIG. 5) . Furthermore, cyclin D-CDK4 complexes may engage the pRB-E2F pathway to inhibit the pRB-mediated repression of PPARγ 155 . Cyclin D1, conversely, was shown to inhibit adipogenesis by inhibiting p300 and recruiting histone deacetylases to PPAR response elements in the promoter of the lipoprotein lipase. Indeed, cyclin D1-null fibroblasts are prone to adipogenic differentiation 37, 38 .
Conclusions and perspectives
Research carried out during the past two decades indicates that interphase cyclins and CDKs have functions that extend well beyond the regulation of cell cycle progression. However, further work is needed to recon cile often-conflicting models and observations, Although their activity promotes the expression of nuclear respiratory factor 1 (NRF1) through the pRB-E2F pathway, cyclin D1-CDK4 can also directly phosphorylate and inactivate NRF1, leading to decreased transcription of mitochondrial proteins by mitochondrial transcription factor A (mtTFA). Moreover, the activity of mitochondria is directly stimulated by cyclin B1-CDK1, whereas binding of cyclin D1 to voltage-dependent anion channel protein (VDAC) prevents hexokinase 2 activation and the use of glucose in mitochondria. In pancreatic β-cells, cyclin D-CDK4 complexes promote insulin secretion through the E2F-mediated expression of the potassium ATP channel component KIR6.2. Insulin, in turn, induces the expression of D-type cyclins through a positive feedback loop. In adipocytes, adipogenesis is inhibited by the interaction of cyclin D1 with the histone acetyltransferase p300, which leads to inhibition of the transcription factor peroxisome proliferator-activated receptor-γ (PPARγ). Conversely, adipogenesis is activated by cyclin D3-CDK4-mediated PPARγ phosphorylation. Gluconeogenesis is inhibited in hepatocytes by cyclin D1-CDK4-dependent phosphorylation and activation of the acetyltransferase GCN5, which acetylates and inactivates the transcription factor PPARγ co-activator 1α (PGC1α). In addition, cyclin D1 can bind to and inactivate the transcription factor hepatocyte nuclear factor 4α (HNF4α), resulting in deficient lipid metabolism. a task that is perhaps confounded by the overlapping and/or compensatory roles of the different cyclin and CDK proteins in mammals. Dysregulation of cell cycle proteins is commonly found in several pathological conditions, including cancer, neurodegeneration and cardiac disease, but the relevance of non-canonical functions of cell cycle proteins in controlling processes other than cell proliferation -such as transcription, cell death, differentiation and metabolism -remains to be fully explored. Some of the proposed non-canonical roles may not reflect a normal physiological protein function, but rather a gain-of-function event that occurs in tumour cells as a consequence of cyclin and/or CDK overexpression. Given that several inhibitors of CDK4/6 kinase activity are currently in clinical trials 156, 157 , it will be important to elucidate which of these cell cycleindependent roles of cyclins and CDKs truly contribute to tumorigenesis in vivo. According to the prevailing model, the main role of CDK4 and CDK6 is to inactivate pRB. Indeed, inhibition of CDK4 and CDK6 has no effect on the proliferation of tumour cells that have lost pRB expression 158 . Given the increasing number of reported CDK4/6 substrates, it remains to be seen whether CDK4/6 inhibition in pRB-negative tumour cells affects other non-canonical functions of cyclin D-CDK4/6 kinases and, by doing so, contributes to the therapeutic effect.
